Why Is Marvell Stock Up?
Semiconductor and data infrastructure company Marvell Technology (NASDAQ:MRVL) absolutely trounced…
Sell
42
BBH Quote, Financials, Valuation and Earnings
Last price:
$160.35
Seasonality move
:
2.22%
Day range:
$159.92 - $160.33
52-week range:
$151.35 - $183.64
Dividend yield:
0.78%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
2.5K
Avg. volume:
13.3K
1-year change:
-5.84%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BBH
VanEck Biotech ETF
|
-- | -- | -- | -- | -- |
|
FTXH
First Trust Nasdaq Pharmaceuticals ETF
|
-- | -- | -- | -- | -- |
|
FXH
First Trust Health Care AlphaDEX Fund
|
-- | -- | -- | -- | -- |
|
IHF
iShares US Healthcare Providers ETF
|
-- | -- | -- | -- | -- |
|
PJP
Invesco Pharmaceuticals ETF
|
-- | -- | -- | -- | -- |
|
RSPH
Invesco S&P 500 Eql Wght Health Care ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BBH
VanEck Biotech ETF
|
$160.63 | -- | -- | -- | $1.25 | 0.78% | -- |
|
FTXH
First Trust Nasdaq Pharmaceuticals ETF
|
$27.14 | -- | -- | -- | $0.13 | 1.65% | -- |
|
FXH
First Trust Health Care AlphaDEX Fund
|
$106.66 | -- | -- | -- | $0.09 | 0.41% | -- |
|
IHF
iShares US Healthcare Providers ETF
|
$49.71 | -- | -- | -- | $0.10 | 0.83% | -- |
|
PJP
Invesco Pharmaceuticals ETF
|
$83.58 | -- | -- | -- | $0.22 | 0.96% | -- |
|
RSPH
Invesco S&P 500 Eql Wght Health Care ETF
|
$30.05 | -- | -- | -- | $0.06 | 0.69% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BBH
VanEck Biotech ETF
|
-- | 0.969 | -- | -- |
|
FTXH
First Trust Nasdaq Pharmaceuticals ETF
|
-- | 0.995 | -- | -- |
|
FXH
First Trust Health Care AlphaDEX Fund
|
-- | 1.264 | -- | -- |
|
IHF
iShares US Healthcare Providers ETF
|
-- | 1.647 | -- | -- |
|
PJP
Invesco Pharmaceuticals ETF
|
-- | 0.821 | -- | -- |
|
RSPH
Invesco S&P 500 Eql Wght Health Care ETF
|
-- | 1.245 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BBH
VanEck Biotech ETF
|
-- | -- | -- | -- | -- | -- |
|
FTXH
First Trust Nasdaq Pharmaceuticals ETF
|
-- | -- | -- | -- | -- | -- |
|
FXH
First Trust Health Care AlphaDEX Fund
|
-- | -- | -- | -- | -- | -- |
|
IHF
iShares US Healthcare Providers ETF
|
-- | -- | -- | -- | -- | -- |
|
PJP
Invesco Pharmaceuticals ETF
|
-- | -- | -- | -- | -- | -- |
|
RSPH
Invesco S&P 500 Eql Wght Health Care ETF
|
-- | -- | -- | -- | -- | -- |
VanEck Biotech ETF vs. Competitors
-
Which has Higher Returns BBH or FTXH?
First Trust Nasdaq Pharmaceuticals ETF has a net margin of -- compared to VanEck Biotech ETF's net margin of --. VanEck Biotech ETF's return on equity of -- beat First Trust Nasdaq Pharmaceuticals ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BBHVanEck Biotech ETF-- -- -- FTXHFirst Trust Nasdaq Pharmaceuticals ETF-- -- -- -
What do Analysts Say About BBH or FTXH?
VanEck Biotech ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand First Trust Nasdaq Pharmaceuticals ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that VanEck Biotech ETF has higher upside potential than First Trust Nasdaq Pharmaceuticals ETF, analysts believe VanEck Biotech ETF is more attractive than First Trust Nasdaq Pharmaceuticals ETF.
Company Buy Ratings Hold Ratings Sell Ratings BBHVanEck Biotech ETF0 0 0 FTXHFirst Trust Nasdaq Pharmaceuticals ETF0 0 0 -
Is BBH or FTXH More Risky?
VanEck Biotech ETF has a beta of 0.738, which suggesting that the stock is 26.201% less volatile than S&P 500. In comparison First Trust Nasdaq Pharmaceuticals ETF has a beta of 0.664, suggesting its less volatile than the S&P 500 by 33.633%.
-
Which is a Better Dividend Stock BBH or FTXH?
VanEck Biotech ETF has a quarterly dividend of $1.25 per share corresponding to a yield of 0.78%. First Trust Nasdaq Pharmaceuticals ETF offers a yield of 1.65% to investors and pays a quarterly dividend of $0.13 per share. VanEck Biotech ETF pays -- of its earnings as a dividend. First Trust Nasdaq Pharmaceuticals ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BBH or FTXH?
VanEck Biotech ETF quarterly revenues are --, which are smaller than First Trust Nasdaq Pharmaceuticals ETF quarterly revenues of --. VanEck Biotech ETF's net income of -- is lower than First Trust Nasdaq Pharmaceuticals ETF's net income of --. Notably, VanEck Biotech ETF's price-to-earnings ratio is -- while First Trust Nasdaq Pharmaceuticals ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for VanEck Biotech ETF is -- versus -- for First Trust Nasdaq Pharmaceuticals ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BBHVanEck Biotech ETF-- -- -- -- FTXHFirst Trust Nasdaq Pharmaceuticals ETF-- -- -- --
-
Which has Higher Returns BBH or FXH?
First Trust Health Care AlphaDEX Fund has a net margin of -- compared to VanEck Biotech ETF's net margin of --. VanEck Biotech ETF's return on equity of -- beat First Trust Health Care AlphaDEX Fund's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BBHVanEck Biotech ETF-- -- -- FXHFirst Trust Health Care AlphaDEX Fund-- -- -- -
What do Analysts Say About BBH or FXH?
VanEck Biotech ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand First Trust Health Care AlphaDEX Fund has an analysts' consensus of -- which suggests that it could fall by --. Given that VanEck Biotech ETF has higher upside potential than First Trust Health Care AlphaDEX Fund, analysts believe VanEck Biotech ETF is more attractive than First Trust Health Care AlphaDEX Fund.
Company Buy Ratings Hold Ratings Sell Ratings BBHVanEck Biotech ETF0 0 0 FXHFirst Trust Health Care AlphaDEX Fund0 0 0 -
Is BBH or FXH More Risky?
VanEck Biotech ETF has a beta of 0.738, which suggesting that the stock is 26.201% less volatile than S&P 500. In comparison First Trust Health Care AlphaDEX Fund has a beta of 0.781, suggesting its less volatile than the S&P 500 by 21.872%.
-
Which is a Better Dividend Stock BBH or FXH?
VanEck Biotech ETF has a quarterly dividend of $1.25 per share corresponding to a yield of 0.78%. First Trust Health Care AlphaDEX Fund offers a yield of 0.41% to investors and pays a quarterly dividend of $0.09 per share. VanEck Biotech ETF pays -- of its earnings as a dividend. First Trust Health Care AlphaDEX Fund pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BBH or FXH?
VanEck Biotech ETF quarterly revenues are --, which are smaller than First Trust Health Care AlphaDEX Fund quarterly revenues of --. VanEck Biotech ETF's net income of -- is lower than First Trust Health Care AlphaDEX Fund's net income of --. Notably, VanEck Biotech ETF's price-to-earnings ratio is -- while First Trust Health Care AlphaDEX Fund's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for VanEck Biotech ETF is -- versus -- for First Trust Health Care AlphaDEX Fund. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BBHVanEck Biotech ETF-- -- -- -- FXHFirst Trust Health Care AlphaDEX Fund-- -- -- --
-
Which has Higher Returns BBH or IHF?
iShares US Healthcare Providers ETF has a net margin of -- compared to VanEck Biotech ETF's net margin of --. VanEck Biotech ETF's return on equity of -- beat iShares US Healthcare Providers ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BBHVanEck Biotech ETF-- -- -- IHFiShares US Healthcare Providers ETF-- -- -- -
What do Analysts Say About BBH or IHF?
VanEck Biotech ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand iShares US Healthcare Providers ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that VanEck Biotech ETF has higher upside potential than iShares US Healthcare Providers ETF, analysts believe VanEck Biotech ETF is more attractive than iShares US Healthcare Providers ETF.
Company Buy Ratings Hold Ratings Sell Ratings BBHVanEck Biotech ETF0 0 0 IHFiShares US Healthcare Providers ETF0 0 0 -
Is BBH or IHF More Risky?
VanEck Biotech ETF has a beta of 0.738, which suggesting that the stock is 26.201% less volatile than S&P 500. In comparison iShares US Healthcare Providers ETF has a beta of 0.786, suggesting its less volatile than the S&P 500 by 21.371%.
-
Which is a Better Dividend Stock BBH or IHF?
VanEck Biotech ETF has a quarterly dividend of $1.25 per share corresponding to a yield of 0.78%. iShares US Healthcare Providers ETF offers a yield of 0.83% to investors and pays a quarterly dividend of $0.10 per share. VanEck Biotech ETF pays -- of its earnings as a dividend. iShares US Healthcare Providers ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BBH or IHF?
VanEck Biotech ETF quarterly revenues are --, which are smaller than iShares US Healthcare Providers ETF quarterly revenues of --. VanEck Biotech ETF's net income of -- is lower than iShares US Healthcare Providers ETF's net income of --. Notably, VanEck Biotech ETF's price-to-earnings ratio is -- while iShares US Healthcare Providers ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for VanEck Biotech ETF is -- versus -- for iShares US Healthcare Providers ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BBHVanEck Biotech ETF-- -- -- -- IHFiShares US Healthcare Providers ETF-- -- -- --
-
Which has Higher Returns BBH or PJP?
Invesco Pharmaceuticals ETF has a net margin of -- compared to VanEck Biotech ETF's net margin of --. VanEck Biotech ETF's return on equity of -- beat Invesco Pharmaceuticals ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BBHVanEck Biotech ETF-- -- -- PJPInvesco Pharmaceuticals ETF-- -- -- -
What do Analysts Say About BBH or PJP?
VanEck Biotech ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco Pharmaceuticals ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that VanEck Biotech ETF has higher upside potential than Invesco Pharmaceuticals ETF, analysts believe VanEck Biotech ETF is more attractive than Invesco Pharmaceuticals ETF.
Company Buy Ratings Hold Ratings Sell Ratings BBHVanEck Biotech ETF0 0 0 PJPInvesco Pharmaceuticals ETF0 0 0 -
Is BBH or PJP More Risky?
VanEck Biotech ETF has a beta of 0.738, which suggesting that the stock is 26.201% less volatile than S&P 500. In comparison Invesco Pharmaceuticals ETF has a beta of 0.587, suggesting its less volatile than the S&P 500 by 41.255%.
-
Which is a Better Dividend Stock BBH or PJP?
VanEck Biotech ETF has a quarterly dividend of $1.25 per share corresponding to a yield of 0.78%. Invesco Pharmaceuticals ETF offers a yield of 0.96% to investors and pays a quarterly dividend of $0.22 per share. VanEck Biotech ETF pays -- of its earnings as a dividend. Invesco Pharmaceuticals ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BBH or PJP?
VanEck Biotech ETF quarterly revenues are --, which are smaller than Invesco Pharmaceuticals ETF quarterly revenues of --. VanEck Biotech ETF's net income of -- is lower than Invesco Pharmaceuticals ETF's net income of --. Notably, VanEck Biotech ETF's price-to-earnings ratio is -- while Invesco Pharmaceuticals ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for VanEck Biotech ETF is -- versus -- for Invesco Pharmaceuticals ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BBHVanEck Biotech ETF-- -- -- -- PJPInvesco Pharmaceuticals ETF-- -- -- --
-
Which has Higher Returns BBH or RSPH?
Invesco S&P 500 Eql Wght Health Care ETF has a net margin of -- compared to VanEck Biotech ETF's net margin of --. VanEck Biotech ETF's return on equity of -- beat Invesco S&P 500 Eql Wght Health Care ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BBHVanEck Biotech ETF-- -- -- RSPHInvesco S&P 500 Eql Wght Health Care ETF-- -- -- -
What do Analysts Say About BBH or RSPH?
VanEck Biotech ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco S&P 500 Eql Wght Health Care ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that VanEck Biotech ETF has higher upside potential than Invesco S&P 500 Eql Wght Health Care ETF, analysts believe VanEck Biotech ETF is more attractive than Invesco S&P 500 Eql Wght Health Care ETF.
Company Buy Ratings Hold Ratings Sell Ratings BBHVanEck Biotech ETF0 0 0 RSPHInvesco S&P 500 Eql Wght Health Care ETF0 0 0 -
Is BBH or RSPH More Risky?
VanEck Biotech ETF has a beta of 0.738, which suggesting that the stock is 26.201% less volatile than S&P 500. In comparison Invesco S&P 500 Eql Wght Health Care ETF has a beta of 0.871, suggesting its less volatile than the S&P 500 by 12.877%.
-
Which is a Better Dividend Stock BBH or RSPH?
VanEck Biotech ETF has a quarterly dividend of $1.25 per share corresponding to a yield of 0.78%. Invesco S&P 500 Eql Wght Health Care ETF offers a yield of 0.69% to investors and pays a quarterly dividend of $0.06 per share. VanEck Biotech ETF pays -- of its earnings as a dividend. Invesco S&P 500 Eql Wght Health Care ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BBH or RSPH?
VanEck Biotech ETF quarterly revenues are --, which are smaller than Invesco S&P 500 Eql Wght Health Care ETF quarterly revenues of --. VanEck Biotech ETF's net income of -- is lower than Invesco S&P 500 Eql Wght Health Care ETF's net income of --. Notably, VanEck Biotech ETF's price-to-earnings ratio is -- while Invesco S&P 500 Eql Wght Health Care ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for VanEck Biotech ETF is -- versus -- for Invesco S&P 500 Eql Wght Health Care ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BBHVanEck Biotech ETF-- -- -- -- RSPHInvesco S&P 500 Eql Wght Health Care ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is General Electric Stock Going Up?
General Electric Company, doing business these days as GE Aerospace…
Where Will Cisco Systems Stock Be in 10 Years?
Cisco Systems, Inc. (NASDAQ:CSCO) has enjoyed its position as a…
Stock Ideas
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 40x
Buy
51
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Sell
44
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Sell
1
IONQ alert for Jan 9
IonQ [IONQ] is down 38.82% over the past day.
Sell
40
QMCO alert for Jan 9
Quantum [QMCO] is down 30.08% over the past day.
Sell
47
MATW alert for Jan 9
Matthews International [MATW] is up 14.21% over the past day.
